SWISH Trial (Strategies for Weaning Infants on Supportive High Flow) (SWISH)

Randomised Control Trial Comparing High Flow Weaning Strategies for Infants With Bronchiolitis: Pilot Study

Bronchiolitis is a common type of chest infection that tends to affect babies and young children under a year old. In older children and adults, the same viruses that cause bronchiolitis lead to the 'common cold'.

The symptoms of bronchiolitis are like a common cold and include a blocked or runny nose, a cough and a mildly raised temperature.

Bronchiolitis affects the bronchioles which are the smaller breathing tubes in the lungs. They produce more mucus than usual and become swollen, leading to a cough and a runny nose. In more severe cases, the tubes become clogged up with mucus which causes breathing problems.

In some babies, the breathing problems may present as breathing fast, with in-drawing of the muscles around the rib cage, and in rare cases, very young babies with bronchiolitis may stop breathing for brief periods ('apnoea'). The illness usually starts with a mild runny nose or cough, gets worse over three to five days or so, and then slowly gets better, usually lasting about 10 to 14 days in total.

Around 2 in 100 infants with bronchiolitis will need to spend some time in hospital during the course of their illness. This is usually for one of two reasons: they need oxygen treatment to keep their oxygen saturations within acceptable levels or they cannot manage to feed from the breast or a bottle because of a blocked nose or difficulty breathing.

Here at the Children's Hospital for Wales we are using 'High flow' to deliver oxygen. This is a relatively new concept on the general paediatric wards, and more established in a setting such as High Dependency Unit (HDU). However, we have been using it successfully on the wards for the last 3 years.

High flow device delivering a mixture of oxygen and air at high flow to help open the child's airways so that their lungs can add oxygen to their blood. It is given through a set of prongs (short plastic tubes) inserted just inside the nostrils.

Research has shown that the early use of high flow can reduce the chances of the child needing escalation of care to a high dependency unit or paediatric intensive care unit.

The investigators are interested in studying the process of weaning high flow support once the child is over the worst of their illness. This will enable the investigators to use the most effective method of weaning babies from their high flow, and ready for discharge. This has the potential to reduce the number of hours spent in hospital for babies and their parents or guardians.

Study Overview

• Status: Recruiting
• Conditions: Respiratory Disease; Bronchiolitis, Viral; Infant Morbidity
• Intervention / Treatment: Device: High flow nasal cannula support

Detailed Description

Bronchiolitis is the commonest respiratory infection in infancy leading to hospital admission. 46 per 1000 infants were admitted to hospital with bronchiolitis in England in 2011 and more recent studies suggest this number has remained static. This has a significant cost burden on the NHS. Respiratory support, mainly oxygenation, and keeping infants well hydrated are the mainstay of management in hospital.

Respiratory support has traditionally been the domain of intensive care settings. This has been provided through an escalation of therapy from simple oxygen delivery by nasal cannula, to non-invasive ventilation with Continuous Positive Airway Pressure (CPAP) and finally to intubation with mechanical ventilation. These latter two strategies require highly skilled staff, so are costly, and are associated with a greater incidence of adverse events including ventilator-induced lung injury, barotrauma, and potential neurotoxicity associated with sedation. Over the last decade High Flow Nasal Cannula (HFNC) therapy has emerged as a new method to provide respiratory support for bronchiolitis. HFNC therapy works by delivering an increased volume of air and oxygen into the nasal passages than standard sub-nasal oxygen therapy, using a higher flow of humidified and heated gas. These increased flow rates exceed peak inspiratory flow and thereby result in more efficient delivery of oxygen to the terminal airways. Physiological studies have demonstrated reduced work of breathing and improved gas exchange. The PARIS study has demonstrated that HFNC can be used in a ward setting to reduce admission rates to the Paediatric Intensive Care Unit (PICU). 12% of the study population receiving HFNC needed escalation to PICU compared to 23% receiving standard care (oxygen therapy). The safety data from the PARIS study shows no difference in adverse effects between HFNC and standard oxygen therapy. Numerous studies over the last three decades have investigated the role of various medications in managing infants with bronchiolitis including adrenaline, steroids, salbutamol, and hypertonic saline; none of these studies have definitively changed the outcome of the disease nor the length of stay in hospital. Although the PARIS study showed a reduction in number of patients requiring escalation of care, it did not demonstrate any difference to the total length of stay in hospital.

Aim Since HFNC is a relatively new method of providing respiratory support in bronchiolitis, there is lack of evidence on weaning strategy. The investigators aim to identify the weaning strategy most effective for infants, up to 12 months of age, supported on HFNC for bronchiolitis. This may lead to shorter total length of stay in hospital, without compromising their care. Infants with bronchiolitis who are on HFNC (the devices used will be Airvo 2, Fisher & Paykel Healthcare) will be on a flow of 2L/kg/min (maximum 20L/min) and variable oxygen concentration to maintain target oxygen saturations >90%. The participants will be randomised into one of two arms for weaning a) titrating oxygen to FiO2 21% and then stopping HFNC b) titrating oxygen to FiO2 30% and switching HFNC to low flow oxygen.

• Study Type: Interventional
• Enrollment (Estimated): 128
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Martin Edwards; Phone Number: 02920743481; Email: martin.edwards4@wales.nhs.uk

Study Locations

• United Kingdom
  • Cardiff, United Kingdom, CF14 4XW
    • Recruiting
    • Children's Hospital for Wales
    • Contact: Martin Edwards; Phone Number: 02920745411; Email: martin.edwards4@wales.nhs.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 weeks to 1 year (Child)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Clinical diagnosis of bronchiolitis
• Age >4 weeks and <12 months
• Needs HFNC respiratory support in a ward setting

Exclusion Criteria:

• Requirement for CPAP or invasive ventilation
• Low level of consciousness
• Apnoeas*
• Cyanotic heart disease
• Basilar skull fracture
• Upper airway obstruction
• Craniofacial malformations
• Infants on home oxygen
• Ex-premature infants (born at <32 weeks gestation)
• Ready to wean high flow after <12 hours of its initiation
• Weight >10kg

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: A: wean to 30%; wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.	Device: High flow nasal cannula support; airvo2 highflow devices will be used.
Active Comparator: B: wean to 21%; wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.	Device: High flow nasal cannula support; airvo2 highflow devices will be used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time taken to wean off the highflow machine as measured in minutes and hours.	The primary outcome is the comparison of time taken from the patient being ready to wean HFNC to discontinuing any respiratory support. This will be measured in minutes and hours and a comparison made between the two intervention arms.	2 YEARS

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
a)Total length of time on supplemental oxygen	Total length of time on supplemental oxygen	2 YEARS
b)Total length of time on High flow nasal cannula	Total length of time on High flow nasal cannula	2 YEARS
c)Rates of failure of weaning strategy	Rates of failure of weaning strategy	2 YEARS
d)Readmission rates to hospital	Readmission rates to hospital	2 YEARS
e)Acceptability by parents of the use of the highflow as assessed by a standardised questionnaire.	A standardised questionnaire will be given to parents to complete while their child is on highflow to assess how they feel about the use of the highflow. Do they percieve their child to be comfortable?	2 YEARS
f)Acceptability by healthcare professionals of the use of the highflow as assessed by a standardised questionnaire.	A standardised questionnaire will be given to parents to complete while their child is on highflow to assess how they feel about the use of the highflow. Do they percieve their child to be comfortable?	2 YEARS

Collaborators and Investigators

• Sponsor: Cardiff and Vale University Health Board

Study record dates

Study Major Dates

• Study Start (Actual): October 6, 2023
• Primary Completion (Estimated): October 6, 2025
• Study Completion (Estimated): October 6, 2025

Study Registration Dates

• First Submitted: February 24, 2020
• First Submitted That Met QC Criteria: February 26, 2020
• First Posted (Actual): February 27, 2020

Study Record Updates

• Last Update Posted (Estimated): February 7, 2024
• Last Update Submitted That Met QC Criteria: February 6, 2024
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Virus Diseases; Infections; Respiratory Tract Infections; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Bronchitis; Bronchiolitis; Respiration Disorders; Respiratory Tract Diseases; Bronchiolitis, Viral
• Other Study ID Numbers: 19/OCT/7769

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No